![Benjamin Scruggs](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Benjamin Scruggs
Amministratore Delegato presso
Altis Biosystems, Inc.
Profilo
Benjamin Scruggs currently works at Altis Biosystems, Inc., as Chief Executive Officer & Director, Veralox Therapeutics, Inc., as Director from 2021, IMMvention Therapeutix, Inc., as Director, Tune Therapeutics, Inc., as Senior Director from 2022, and Hatteras Venture Partners, as Partner from 2025.
Dr. Scruggs received his doctorate degree in 2012 from Washington University in St. Louis and undergraduate degree in 2006 from Vanderbilt University.
Posizioni attive di Benjamin Scruggs
| Società | Posizione | Inizio |
|---|---|---|
Hatteras Venture Partners
 Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Investitore di Private Equity | 01/01/2021 |
IMMvention Therapeutix, Inc.
 IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Direttore/Membro del Consiglio | - |
Veralox Therapeutics, Inc.
 Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Direttore/Membro del Consiglio | 01/06/2021 |
Tune Therapeutics, Inc.
 Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Direttore/Membro del Consiglio | 01/01/2022 |
Altis Biosystems, Inc.
 Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Amministratore Delegato | 01/02/2023 |
Formazione di Benjamin Scruggs
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
94
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Washington University in St. Louis
 Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners invests in companies located in the United States. The firm targets companies operating in the fields of biopharmaceuticals, medical devices, diagnostics, healthcare IT and human medicine. It provides financing for seed and early stage capital requirements and also makes co-investments. | Finance |
Veralox Therapeutics, Inc.
Veralox Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services for clinical stage company | Health Technology |
Altis Biosystems, Inc.
Altis Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Develops stem cell technology designed to recreate the human intestinal epithelium and colonic epithelium for compound screening and microbiome research | Health Technology |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. BiotechnologyHealth Technology Operates epigenome treatment medicines | Health Technology |
